Eritadenine

Preliminary

Nucleoside derivative (adenosine analog)

Mechanism of Action

Eritadenine lowers cholesterol through inhibition of S-adenosyl-L-homocysteine hydrolase (SAHH), which alters phospholipid metabolism in hepatocytes. This shifts the phosphatidylcholine-to-phosphatidylethanolamine ratio, reducing VLDL assembly and secretion from the liver. The mechanism is distinct from and complementary to lovastatin's HMG-CoA reductase inhibition, providing dual cholesterol-lowering pathways when both compounds are present in the mushroom matrix.

Research Notes

King TrumpetMushroom

Eritadenine was originally characterized in Lentinula edodes (shiitake) and subsequently identified in P. eryngii. Animal studies demonstrated significant reductions in serum cholesterol, VLDL, and triglycerides through the SAHH inhibition mechanism. The compound acts rapidly — cholesterol-lowering effects observed within 7 days in animal models. Human clinical trial data specific to eritadenine from P. eryngii is lacking.

Found In 1 Herb

King Trumpet

Mushroom

3D Molecular Structure

Nucleoside derivative (adenosine analog)

Drag to rotate · Click atoms to explore

Eritadenine

Nucleoside derivative (adenosine analog)Bioactive phytochemical with therapeutic properties

Representative pattern: C₄H₂NO

Atoms

Carbon

Oxygen

Nitrogen

Hydrogen

Live Research

Open on PubMed

This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare practitioner before using any herbal product.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This content is for educational purposes only and is not a substitute for professional medical advice.